Sinha Satyabrata, Chunder Neelanjana, Mukherjee Nupur, Alam Neyaz, Roy Anup, Roychoudhury Susanta, Kumar Panda Chinmay
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, 700026, India.
Ann Surg Oncol. 2008 Apr;15(4):1070-80. doi: 10.1245/s10434-007-9790-0. Epub 2008 Feb 1.
This study attempts to understand the association of candidate tumour suppressor genes SH3GL2, CDKN2A (p16-p14) and CDKN2B (p15) in development of early-onset (group A) and late-onset (group B) breast carcinoma (BC).
Deletion, methylation, and mutation of the candidate tumour suppressor genes (TSGs) were analysed in 47 group A and 59 group B samples. Immunohistochemical analysis was used to identify the expression status of SH3GL2 and p16. Clinicopathological correlation of the alterations was analysed by the chi-square and log-rank tests.
Higher frequency of overall alterations (46-62%) in SH3GL2 and p16-p14 than p15 (22-26%) indicated their importance in BC. Deletion frequencies were in the following order: group A: p14 (43%) > p16 (42%) > SH3GL2 (38%) > p15 (33%) and group B: p14 (36%) > p16 (33%) > SH3GL2 (31%) > p15 (14%) while, methylation frequencies were: group A: SH3GL2 (34%) > p16 (28%) > p14 (26%) > p15 (15%) and group B: SH3GL2 (36%) > p16 (31%) > p14 (29%) > p15 (15%). Infrequent mutation was observed only in CDKN2A common exon-2. Immunohistochemical analysis showed significant association between expression of SH3GL2 and p16 with their deletion (P = 0.01 and 0.02, respectively) and methylation status (P = 0.007 and 0.01, respectively). In group A, overall alterations of SH3GL2 showed significant association with CDKN2A locus with significant prognostic implications, whereas CDKN2A and CDKN2B loci were associated in both groups.
The molecular mechanisms involving CDKN2A inactivation seem to follow similar pathway in the pathogenesis of both age groups of BC while significant association of SH3GL2 with CDKN2A might play a synergistic role in the development of group A.
本研究旨在了解候选肿瘤抑制基因SH3GL2、CDKN2A(p16 - p14)和CDKN2B(p15)在早发型(A组)和晚发型(B组)乳腺癌(BC)发生发展中的关联。
对47例A组和59例B组样本中的候选肿瘤抑制基因(TSGs)的缺失、甲基化和突变情况进行分析。采用免疫组织化学分析来确定SH3GL2和p16的表达状态。通过卡方检验和对数秩检验分析这些改变与临床病理特征的相关性。
SH3GL2和p16 - p14的总体改变频率(46 - 62%)高于p15(22 - 26%),表明它们在乳腺癌中具有重要性。缺失频率顺序如下:A组:p14(43%)> p16(42%)> SH3GL2(38%)> p15(33%);B组:p14(36%)> p16(33%)> SH3GL2(31%)> p15(14%)。甲基化频率为:A组:SH3GL2(34%)> p16(28%)> p14(26%)> p15(15%);B组:SH3GL2(36%) > p16(31%)> p14(29%)> p15(15%)。仅在CDKN2A的常见外显子2中观察到罕见突变。免疫组织化学分析显示,SH3GL2和p16的表达与其缺失(分别为P = 0.01和0.02)及甲基化状态(分别为P = 0.007和0.01)之间存在显著关联。在A组中,SH3GL2的总体改变与CDKN2A基因座显著相关,具有显著的预后意义,而在两组中CDKN2A和CDKN2B基因座均相关。
在两个年龄组乳腺癌的发病机制中,涉及CDKN2A失活的分子机制似乎遵循相似的途径,而SH3GL2与CDKN2A的显著关联可能在A组的发生发展中起协同作用。